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1. Introduction 
Bleeding esophageal varices (BEV) is a common and highly lethal complication of cirrhosis 
of the liver (Graham & Smith, 1981; Smith & Graham, 1982; Burroughs et al., 1989; Bornman 
et al., 1994; Khan et al., 2006; Orloff et al., 1977; Mikkelsen, 1974; Terblanche et al., 1989; & 
D’Amico et al., 1995) The mortality rate associated with BEV is highest during the period 
surrounding the episode of acute bleeding. If the varices remain untreated after recovery 
from a bout of acute bleeding, we ( Orloff et al., 1977) and others observed a 95% incidence 
of recurrent bleeding, and death within 2 to 5 years in 90% to 100% of the patients. 
Recurrent bleeding has been reported to develop most often within the first few days after 
the acute bleeding episode (Graham & Smith, 1981; Smith & Graham, 1982). Thus, it is clear 
that emergency treatment of acute bleeding is of paramount importance in the care of 
patients with portal hypertension and esophagogastric varices.  
Because of the over-riding importance of emergency treatment of variceal bleeding, from 
1958 to 2011 we conducted and reported studies of emergency therapy in patients with 
cirrhosis (Orloff, 1967; Orloff et al., 1980; Orloff et al., 1992); Orloff et al., 1994; Orloff et al., 
1995a; Orloff et al., 2009a; Orloff et al., 2009b; Orloff et al., 2011a; Orloff et al., 2011b; Orloff 
et al., 2010; Orloff et al., 2011c; Orloff et al., 2011d; Orloff et al, 2011e; Orloff et al., 2011f; 
Orloff et al., 2011g; Orloff et al., 2011h; Orloff et al., 2011i). Our studies have been 
distinguished by three features that, together, make them different from other reported 
investigations. All patients admitted to our institution with cirrhosis and BEV (“all 
comers”), regardless of their condition, were included without selection; the specific 
emergency treatment undergoing evaluation was administered within 24 hours and usually 
within 8 hours of initial contact; and our studies were prospective, meaning that a well-
defined protocol was consistently used and data were collected on-line. Evaluation, 
prevention, and treatment of portal-systemic encephalopathy (PSE) were an important part 
of each of our studies.  
2. The Eck fistula  
In 1877, Nikolai V. Eck (1849-1908), a 29-year-old military surgeon working in the Military 
Medical Academy in St. Petersburg, published a brief article describing his experiments and 
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technique for creating a portacaval shunt (Eck fistula) in eight dogs (Eck, 1877). This was not 
only the beginning of the surgical treatment of portal hypertension but also the first vascular 
anastomosis. In his article, Eck stated: “I am conducting these experiments with the purpose 
of clarifying some physiologic problems as well as to determine whether it would be 
possible to treat some cases of mechanical ascites by means of forming such a fistula. I 
operated on 8 dogs, one recovered completely and lived in the laboratory for 2.5 months. 
Because of lack of attention, he ran away. I had to postpone further experiments because I 
was called to join the active army.”  
Eck’s work would probably have remained unknown outside Russia had it not been for 
Ivan Pavlov (1849-1936), who used the procedure extensively in laboratory studies of liver 
physiology and named the operation the Eck fistula, giving full credit to Eck for its 
invention (Hahn et al., 1893; Pavlov, 1893). The landmark description by Pavlov et al. of 
portal-systemic encephalopathy (PSE) following feeding meat to dogs with an Eck fistula, 
which they called “meat intoxication,” was part of the work that resulted in Pavlov’s 
receiving the Nobel Prize in 1904 for his contributions on the physiology of digestion. 
Pavlov spent his entire career at the Military Medical Academy in St. Petersburg, the same 
institution where Eck developed the portacaval shunt. Since its original description, the Eck 
fistula has been used extensively for a wide range of studies in animals and humans and 
clinically for the treatment of the life-threatening complications of portal hypertension.  
3. Portal-Systemic Encephalopathy (PSE)  
Hepatic encephalopathy is a neuropsychiatric disorder that results from impaired liver 
function. It occurs in two distinct forms: (1) in acute or fulminant hepatic failure it takes the 
form of a neurological disorder that progresses from altered mental status to coma, generally 
within hours or days, and is associated with increased intracranial pressure caused by massive 
brain edema; (2) portal-systemic encephalopathy (PSE), which commonly occurs in cirrhosis, 
in which there are spontaneous or created portal-systemic shunts that permit toxins of 
intestinal origin to bypass the liver into the systemic circulation. Neurologically, PSE develops 
slowly, starting with sleep abnormalities, shortened attention span, and muscular 
incoordination, progressing through lethargy, ataxia, stupor, and coma. PSE is often 
precipitated by event such as gastrointestinal bleeding, uremia, hypokalemia, or ingestion of 
excessive amounts of protein. Neuropathologically, PSE is characterized by astrocytic rather 
than neuronal changes, and brain edema and intracranial hypertension are not found.  
Since the description in 1893 of “meat intoxication” in the Eck fistula dog by the Pavlov 
group, animals with a portacaval shunt (PCS) (Eck fistula) have been used extensively for 
research studies of the pathogenesis and treatment of PSE (Hahn et al., 1893). The PCS rat 
has been consistently reported to have neurobehavioral abnormalities when subjected to 
sophisticated testing (Bengtsson et al., 1980; Tricklebank et al., 1978). One of the best animal 
models of chronic recurrent PSE is the dog with a congenital or surgically created PCS 
(Maddison et al., 1991). Animal and human studies have demonstrated that chronic liver 
failure and spontaneous or created PCS result in the accumulation of neurotoxic substances 
in the brain. Two such substances are ammonia and manganese.  
Ammonia derived from colonic bacteria as well as from the deamination of glutamine in the 
small bowel is absorbed by passive diffusion and normally undergoes a high first-pass 
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extraction by the liver (Cordoba & Blei, 1997). In chronic liver failure, hepatic urea synthesis 
declines and this, in addition to portal-systemic shunting, results in increased blood 
ammonia concentrations. Furthermore, cirrhotic patients are hypersensitive to 
ammoniagenic conditions such as an oral protein load or gastrointestinal hemorrhage. An 
illustration of this hypersensitivity is provided by a report of studies in the 1950s in which 
attempts were made to treat ascites in cirrhotic patients with ion-exchange resins that 
absorbed sodium but released ammonium ions (Gabuzda et al., 1952). This treatment led to 
a significant reduction in ascitic volume but precipitated severe PSE in many of the patients 
treated. If present in high concentrations, ammonia has the potential to adversely affect 
central nervous system (CNS) function by several mechanisms, which include a direct effect 
of the ammonium ion on inhibitory and excitatory neurotransmission as well as inhibition of 
the tricarboxylic acid cycle enzyme ketoglutarate dehydrogenase, with potential impairment 
of brain energy metabolism (Szerb & Butterworth, 1992; Lai & Cooper, 1986) However, brain 
energy metabolism does not appear to be impaired in chronic liver failure until very late 
stages associated with isoelectric electroencephalography (EEG) traces (Hindfelt et al., 1977). 
On the other hand, increases of cerebrospinal fluid lactate have been described both in 
cirrhotic patients with PSE (Yao et al., 1987) and in experimental animals with chronic liver 
failure and ammonia-precipitated encephalopathy (Therrien et al., 1991) , findings that are 
consistent with an inhibitory effect of ammonia on cerebral glucose oxidation.  
Other effects of ammonia on cerebral function include a stimulatory effect on L-arginine 
uptake by brain preparations resulting in increased production of nitric oxide (Raghavendra 
Rao et al., 1995) and inhibition of the capacity of astrocytes to accumulate glutamate (Bender 
& Norenberg, 1996; Knecht et al., 1997) a major excitatory neurotransmitter.  
In 1963, we performed a study that subsequently influenced the use of PCS in the treatment 
of portal hypertension and variceal hemorrhage. We examined the influence of the stomal 
size of the portacaval anastomosis, and in turn of the blood flow rate through the 
anastomosis, on peripheral blood ammonia levels (Orloff et al., 1963). Induced ammoniemia 
was studied in two groups of dogs, one of which had large end-to-side PCS measuring at 
autopsy 2.0-4.2 cm in greatest diameter, and the other of which had small end-to-side PCS 
measuring 0.5-1.8 cm in greatest diameter. A third group of intact dogs served as controls. 
Ammoniemia was induced by three standardized methods that consisted of the 
administration by gavage of ammonium citrate (0.5 g/kg), gavage of fresh whole blood (30 
mL/kg) plus urease (4 U/mL), and gavage of fresh whole blood (30 mL/kg) alone. All three 
techniques of ammonium loading resulted in significantly higher mean peak blood 
ammonia levels in the dogs with large shunts than in those with small shunts. Furthermore, 
in the animals with large shunts, markedly elevated blood ammonia concentrations 
persisted for longer periods of time. Measurements of the pressure gradients across the 
shunts at operation revealed a mean gradient of 31.0 mm saline in the small-shunt group as 
compared to only 3.0 mm in the large-shunt group. A consistent inverse relationship was 
demonstrated between the height of the blood ammonia level and the magnitude of the 
pressure gradient across the portacaval anastomosis. Application of Gorlins’ hydraulic 
formula to these studies provided support for the presumption that the magnitude of 
ammoniemia was directly related to the blood flow rate through the shunt. We concluded 
that the stomal size of end-to-side PCS, and in turn the rate of blood flow through the 
shunts, have a definite influence on the concentration of ammonia in the peripheral blood of 
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the dog. These results suggested the possibility of a relationship between shunt size and 
postshunt PSE. The results of this study served as the basis for the subsequent use of 
reduced-caliber PCS in the treatment of variceal bleeding (Sarfeh & Rypins, 1994; Zervox et 
al., 1998). 
In addition to ammonia, chronic liver failure and portal-systemic shunting result in 
increased blood and brain concentrations of manganese (López-Novoa, 1988; Fitzhugh & 
Nelson, 1948; Dashti et al., 1989; & Nuber et al., 1980). Manganese is neurotoxic, affecting 
both neuronal and astrocytic integrity. In the case of astrocytes, exposure to manganese 
results in altered expression of several key astrocytic proteins (Hazell et al., 1999a; Hazell et 
al., 1999b) and Alzheimer type II changes (Weissenborn et al., 1995). 
Other toxins in addition to ammonia and manganese are known to increase in the systemic 
circulation in chronic liver failure. Such toxins include mercaptans, phenols, and short-chain 
fatty acids (Zieve et al., 1974). While there is no convincing evidence that these toxins alone 
cause cerebral dysfunction in chronic liver failure, they could combine with ammonia or 
manganese to act synergistically (Zieve, 1989). 
Recently, attention has been focused on changes in brain neurotransmitter systems as the 
likely mediators of the neuropsychiatric manifestations of PSE in chronic liver failure. 
Recent studies using molecular biological approaches continue to confirm that, when liver 
fails, brain responds with significant alterations in gene expression. In many cases, these 
alterations involve genes that code for neurotransmitter-related proteins, many of which are 
essential for CNS function. Many of the symptoms of early PSE in chronic liver failure, such 
as altered personality, depression, and inverted sleep patterns, are symptoms that have 
classically been associated with alterations in biogenic amine function. FNA extracts of brain 
tissue obtained at autopsy from cirrhotic patients who died in hepatic coma have been 
found to show increased expression of the neuronal isoform of the monoamine-
metabolizing enzyme MAO-A (Mousseau et al., 1997). This increase in MAO-A gene 
expression was found to be associated with increased activities of the enzyme and increased 
densities of catalytic sites on the enzyme protein (Mousseau et al., 1997). Moreover, studies 
of the same brain extracts revealed increased concentrations of homovanillic and –
hydroxyindoleacetic acids, the final metabolites of dopamine and serotonin, respectively 
(Bergeron et al., 1989). Increased concentrations of 5-hydroxyindoleacetic acid were also 
reported in cerebrospinal fluid from patients (Young & Lai, 1980) and experimental animals 
(Bergeron et al., 1995) with chronic liver failure. On the basis of these findings, it has been 
suggested that altered monoaminergic function may be responsible for the early 
neuropsychiatric symptoms of PSE in chronic liver disease (Bergeron et al., 1995; Bergeron et 
al., 1990). 
The “peripheral-type” benzodiazepine receptor (PTBR) is a heterooligomeric protein complex 
located (like MAO-A) on the outer mitochondrial membrane of the astrocyte. Increased 
PTBR gene expression has been reported in brain extracts from rats with PCS (Desjardins et 
al., 1997). This increased gene expression resulted in increased receptor sites in the brains 
and peripheral tissues of these animals as revealed by quantitative receptor 
autoradiography and the high selective PTBR ligant [3H] PK 11195 (Giguère et al., 1992; 
Raghavendra Rao et al., 1994). Increased [3H] PK 11195 binding sites were also reported in 
autopsied brain tissue from cirrhotic patients who died in hepatic coma (Lavoie et al., 1990). 
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There is evidence to suggest that the increased expression of PTBRs in brain in chronic liver 
failure is the consequence of exposure to ammonia and/or manganese. The precise 
mechanism whereby increased expression or activation of PRBRs results in altered brain 
excitability characteristic of PSE has not been established. PCS in the rat results in increased 
gene expression of the constitutive (neuronal) isoform of nitric oxide synthase (nNOS) in 
brain (Raghavendra Rao et al., 1997a). Increased nNOS mRNA is accompanied by increased 
nNOS protein (Raghavendra Rao et al., 1997a) and by increased nNOS enzyme activities. 
Recent evidence suggests that, in addition to an induction in nNOS gene expression, 
increased nNOS activities may also result from a stimulatory effect of ammonia on L-
arginine uptake by neuronal preparations shown both in vitro and in vivo (Raghavendra Rao 
et al., 1997b). Increased production of NO as a consequence of increased nNOS activities 
could contribute to the alterations of cerebral perfusion observed in chronic liver disease 
(Raghavendra Rao et al., 1998). 
The appearance of extrapyramidal symptoms, particularly rigidity, in cirrhotic patients with 
end-stage liver disease has prompted, by analogy with the well-established dopamine 
deficit in Parkinson’s disease, evaluations of the dopamine system in relation to PSE. Studies 
in autopsied brain tissue from cirrhotic patients (Bergeron et al., 1989) and from rats with 
PCS (Bergeron et al., 1995) reveal several-fold increases in concentration of the dopamine 
metabolite homovanillic acid, a finding that could result from increased activities of monoamine 
oxidase reported in the same material (Mousseau et al., 1997). In another study, densities of the 
postsynaptic dopamine D2 receptor were significantly reduced in pallidum/putamen from 
cirrhotic patients (Mousseau et al., 1993) a finding that could have resulted from manganese 
deposition in the brains of these patients (Pomier Layrargues et al., 1995). 
Strategies aimed at the prevention and treatment of PSE in chronic liver failure are of two 
major types, namely, ammonia-lowering strategies and approaches aimed directly at the 
CNS (Cordoba & Blei, 1997; Ferenci et al., 1996). Since PSE is frequently precipitated by 
ammoniagenic situations such as an oral protein load or a gastrointestinal hemorrhage, 
various treatment modalities are aimed at the gut. Such strategies include reduction of the 
absorption of nitrogenous substances arising from bacterial action in the colon. Colonic 
cleansing reduces the luminal ammonia content and lowers blood ammonia content in 
cirrhotic patients (Wolpert et al., 1970). Nonabsorbable disaccharides are routinely used to 
decrease ammonia production in the gut. The action of the most popular substance in this 
class, lactulose, involves increased fecal nitrogen excretion by facilitation of the 
incorporation of ammonia into bacteria as well as a cathartic effect (Cordoba & Blei, 1997). 
Lactulose administered orally reaches the cecum, where it is metabolized by enteric bacteria, 
causing a fall in pH (Brown et al., 1974). The dose is adjusted to produce two or three soft 
bowel movements daily (Cordoba & Blei, 1997).  
Antibiotics such as neomycin are also useful for lowering blood ammonia, mainly by an 
effect on ammonia production by intestinal bacteria. However, neomycin therapy may be 
associated with some toxic side effects (Cordoba & Blei, 1997). More recently, rifaximin, a 
nonabsorbable derivative of the antibiotic rifamycin, has been shown to be effective in 
lowering blood ammonia and has proven to be of superior efficacy compared with lactulose 
(Bismuth et al., 2011; Munoz, 2008). Most of an orally administered dose is eliminated 
unchanged in the feces. Thus, it lacks significant toxicity and side effects because of minimal 
gastrointestinal absorption.  
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Restriction of dietary protein remains a cornerstone of therapy for PSE in cirrhotic patients 
and has been an essential part of our treatment of patients with bleeding esophageal varices 
following portacaval shunt (Wolpert et al., 1970). However, long-term nitrogen restriction is 
potentially harmful and a positive nitrogen balance is necessary to promote liver 
regeneration as well as to increase the capacity of skeletal muscle to remove ammonia in the 
form of glutamine (Lockwood et al., 1979). Protein intake of 1 g/kg per day may be required 
in order to maintain an adequate nitrogen balance (Swart et al., 1989). 
An alternative strategy for the lowering of blood ammonia is the stimulation of ammonia 
fixation (Desjardins et al., 1997). Under normal physiological conditions, ammonia is 
removed by the formation of urea in periportal hepatocytes and by glutamine synthesis in 
perivenous hepatocytes, skeletal muscle, and brain. In cirrhosis, both urea cycle enzymes 
and glutamine synthetase in liver are decreased in activity. Strategies to stimulate residual 
urea cycle activities and/or glutamine synthesis have been tried over the past 20 years. One 
of the most successful agents to be used so far is L-ornithine-L-aspartate (OA). RCTs with 
OA demonstrate significant ammonia lowering and concomitant improvement in 
psychometric test scores in cirrhotic patients with PSE (Kircheis et al., 1997). Studies in 
experimental animals suggest that the metabolic basis for the beneficial effect of OA on 
blood ammonia in chronic liver failure resides in its ability to stimulate residual hepatic urea 
cycle function and also to promote glutamine synthesis, particularly in skeletal muscle (Rose 
et al., 1998). 
Benzoate is also effective in reducing blood ammonia both in patients with inherited urea 
cycle disorders and in cirrhotic patients [64]. In a RCT with sodium benzoate versus 
lactulose, improvement in neuropsychiatric performance was found to be comparable using 
both treatments (Sushma et al., 1992).  
In contrast to the multiple strategies used successfully to lower blood ammonia and 
improve neurological status in patients with chronic liver failure, drugs that act directly on 
neuronal excitability have not been widely applied in this patient group. The major reason 
for this is that the precise neurotransmitter changes responsible for PSE in chronic liver 
failure are still being elucidated. Some attempts to treat PSE in cirrhotic patients with 
benzodiazepine receptor antagonists and dopamine agonists have occurred, but with 
limited success.  
Several RCTs have been performed to assess the efficacy of the benzodiazepine receptor 
antagonist flumazenil in cirrhotic patients with various degrees of severity of PSE [69]. 
Spectacular improvements in neuropsychiatric status were recorded in a subset of patients 
receiving flumazenil (Pomier Layrargues, 1994; Gyr et al., 1996). However, enthusiasm for 
this approach has been tempered by the possible confounding effects of prior exposure to 
benzodiazepines and the seeming lack of correlation between clinical response and blood 
levels of substances with benzodiazepine receptor agonist properties in these patients 
(Butterworth et al., 1995).  
4. Emergency portacaval shunt for bleeding esophageal varices 
Portal-systemic shunt is the only available definitive treatment for portal hypertension-
related bleeding. Numerous studies have shown that a technically satisfactory PSS will 
permanently solve the problem of bleeding in the vast majority of patients. The obvious 
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potential advantage of performing this procedure under emergency circumstances is that, 
unlike other forms of treatment, it can be expected to provide both immediate and 
prolonged control of hemorrhage. The question is, can cirrhotic patients tolerate an 
operation of this magnitude when it is performed as an emergency in the face of bleeding? 
To answer this question, we have conducted prospective studies of emergency PCS (EPCS) 
over the past 47 years, as follows: (1) an unrandomized study of 400 unselected patients 
who underwent EPCS; (2) a RCT of EPCS versus emergency medical therapy involving 43 
patients at our Veterans Administration Hospital; (3) an unrandomized study of 94 
unselected, consecutive patients with Child’s class C cirrhosis; (4) a RCT of portacaval shunt 
versus endoscopic sclerotherapy in 518 unselected patients bleeding from gastric varices; (5) 
an unrandomized study in 12 patients with uncontrollable bleeding from portal 
hypertensive gastropathy; (6) a NIH grant supported RCT of EPCS versus emergency 
endoscopic sclerotherapy (EST) that enrolled 211 patients who have had more than 10 
years of follow-up or until death; and (7) a NIH grant supported RCT of TIPS versus 
EPCS that enrolled 154 patients who have been followed up for 5-10 years (Orloff, 1967; 
Orloff et al., 1980; Orloff et al., 1992; Orloff et al., 1994; Orloff et al., 1995a; Orloff et al., 
2009a; Orloff et al., 2009b; Orloff et al., 2011a; Orloff et al., 2011b; Orloff et al., 2010; Orloff 
et al., 2011c; Orloff et al., 2011d; Orloff et al, 2011e; Orloff et al., 2011f; Orloff et al., 2011g; 
Orloff et al., 2011h; Orloff et al., 2011i; Orloff & Bell, 1983; Bell, et al., 1981; Orloff, 1968; 
Orloff, 1969; Orloff et al., 1974; Orloff et al., 1975; Orloff & Bell, 1986; Orloff et al., 1995b; 
Orloff et al., 1997) . The unique features of our studies that, together, make them different 
from other reported investigations are as follows: (1) EPCS was undertaken within 24 h of 
initial contact of the patient with our institution in one study and within 8 h in the other 
six studies; (2) the patients were unselected, which means that all patients with bleeding 
varices, regardless of their condition (“all comers”), were entered in the studies and 
treated; (3) the studies were prospective, which means that the patients were managed 
according to a well-defined and consistently applied protocol, and specific data were 
collected at the time of diagnosis, treatment, and follow-up; and (4) the patients were 
followed up monthly for the first year and every 3 months thereafter for life, such that the 
1-, 5-, and 10-year follow-up rates were 100, 98, and 97%, respectively. A total of 1,432 
patients have been involved in these studies.  
5. Portal-systemic encephalopathy in our RCT of endoscopic sclerotherapy 
versus emergency portal shunt 
5.1 Quantitation of PSE  
This recently published RCT is representative of all of our studies (Orloff et al., 2009a; Orloff 
et al., 2009b). PSE was quantitated during hospitalizations and at each clinic visit by grading 
4 variously weighted components on a scale of 0 to 4: (1) mental state, (2) asterixis, (3) 
number connection test, and (4) arterial blood ammonia. A PSE Index was calculated 
according to the method of Conn et al. (Conn & Lieberthal, 1978) in which the scores of the 4 
components were added to yield a PSE Sum, and then divided by the maximum possible 
PSE Sum. Mental state was given a weight of 3 and the other components a weight of 1. To 
increase objectivity, a senior faculty gastroenterologist who was not otherwise involved in 
the BEV study evaluated each patient for PSE during the clinic visits. The gastroenterologist 
was “blinded” in that he was not told what therapy the patient had received.  
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The definition of PSE was based on any one of the following criteria: (1) classical signs of 
altered mental status on physical examination performed by an experienced faculty 
physician; (2) classical signs of altered mental status described by outside physicians, close 
relatives of the patient, or the patient himself; (3) a high PSE Index of 0.33 or greater. 
Electroencephalography was not included in the evaluation because it was considered 
cumbersome, costly, and impractical given the numerous programmed and unprogrammed 
outpatient clinic and emergency department visits made by the patients. Patients were 
classified as having recurrent PSE when they had 2 or more episodes of PSE after primary 
therapy.  
5.2 Incidence of PSE 
Patients who were discharged from the hospital and survived more than 30 days after entry 
in the study numbered 93 in the EST group and 89 in the EPCS group. Calculations of the 
incidence and manifestations of recurrent PSE are based on this population. Deaths on or 
before 30 days were considered indeterminate and were unrelated to PSE. Dietary protein 
tolerance up to 80 g per day was observed in all patients before discharge. A 60-g protein 
restriction was prescribed upon discharge. Table 1 and Fig. 1 show data on this group of 
patients. Patients who developed recurrent PSE after discharge from the initial hospital 
admission numbered 33 or 35% in the EST group and 13 or 15% in the EPCS group. The 
difference was highly significant with a P value of 0.001. 
 EST 
(n = 93) 
EPCS 
(n = 89) 
p 
Value 
Incidence of recurrent PSE – n (%) 33 (35) 13 (15) 0.001* 
Incidence of transient PSE – n (%) 3 (3) 3 (3) 1.0 
Length of survival: 
 Total days 
 Total years 
 Total days per patient 
 Total years per patient 
 
133,243 
364.8 
1432.7 
3.9 
 
266,169 
728.7 
2990.7 
8.2 
 
<0.001* 
 
Episodes of recurrent PSE 
 Total episodes – n (n/person) 
 Episodes per year of follow-up 
 Interval between episodes (years) 
 
179 (1.92) 
0.49 
2.03 
 
94 (1.06) 
0.13 
7.74 
 
0.003* 
Hospital readmissions for recurrent PSE 
 Total readmissions – n (n/person) 
 Readmissions per year of follow-up 
 Interval between readmissions (years) 
 
146 (1.57) 
0.40 
2.50 
 
87 (0.98) 
0.12 
8.38 
 
0.003* 
Cause of recurrent PSE episodes – n (%) 
 Dietary protein indiscretion 
 UGI bleeding 
 Infection 
 Alcoholism 
 Uncontrolled diabetes 
 Hepatic failure 
 Other 
 
75 (42) 
57 (32) 
18 (10) 
28 (16) 
2 (1) 
5 (3) 
7 (4) 
 
60 (64) 
8 (9) 
12 (13) 
4 (4) 
11 (12) 
0 (0) 
5 (5) 
<0.001* 
www.intechopen.com
Portal-Systemic Encephalopathy  
in Emergency Treatment of Cirrhosis and Bleeding Esophageal Varices 
 
233 
Timing of first episode of recurrent PSE – n (%)
 First 6 months 
 Second 6 months 
 Year-1 
 Year-2 
 Year-3 
 Year-4 
 Year-5 
 Year >5 
 
17 (52) 
6 (18) 
23 (70) 
4 (12) 
2 (6) 
0 (0) 
1 (3) 
3 (9) 
 
8 (62) 
1 (8) 
9 (69) 
3 (23) 
0 (0) 
0 (0) 
0 (0) 
1 (8) 
0.30 
Timing of all episodes of recurrent PSE – n (%) 
 First 6 months 
 Second 6 months 
 Year-1 
 Year-2 
 Year-3 
 Year-4 
 Year-5 
 Year >5 
 
24 (15) 
31 (19) 
55 (34) 
46 (28) 
18 (11) 
15 (9) 
4 (2) 
26 (16) 
 
23 (24) 
8 (8) 
31 (33) 
32 (34) 
11 (12) 
14 (15) 
1 (1) 
6 (6) 
0.33 
Relationship of recurrent PSE to survival – 
 Years (median, 95% CI) 
 Patient with recurrent PSE: 
    Overall survival 
    Survival after first PSE 
 Patients free of recurrent PSE: 
    Overall survival 
 P value – Recurrent PSE vs. no PSE 
 
 
 
2.90 (1.5, 4.74) 
1.23 (0.94, 3.17) 
 
3.26 (2.00, 4.34) 
0.042* 
 
 
 
5.18 (1.26, Inf) 
4.14 (1.17, Inf) 
 
10.37 (6.19, Inf) 
0.001* 
 
 
High PSE Index – n (%) 
 Patients with PSE Index ≥0.33 
 
 Patients with PSE Index ≥0.33 who 
    had recurrent clinical PSE 
 
19 (20) 
 
 
15 (79) 
 
12 (13) 
 
 
4 (33) 
 
0.24 
 
 
0.022* 
* statistically significant difference 
Table 1. Recurrent PSE in Patients Who Survived >30 Days and Were Discharged from the 
Hospital 
The 93 early survivors in the EST group lived for a collective total of 364.8 years, while the 
89 early survivors who underwent EPCS lived a collective total of 728.7 years, twice as long 
as the EST patients (p<0.001). The patients with recurrent PSE in the EST group had a 
collective total of 179 episodes of PSE and were readmitted to the hospital 146 times for 
treatment of PSE. In contrast, the patients with recurrent PSE following EPCS, experienced 
94 episodes and 87 hospital readmissions. The calculated yearly frequency of PSE episodes 
was 0.49/yr in the EST group and 0.13/yr in the EPCS group, and the calculated hospital 
readmission rate was 0.40/yr in the EST patients and only 0.12/yr in the EPCS patients 
(p=0.003). Expressed as per-patient average, patients in the EST group were hospitalized for 
recurrent PSE every 2.50 years, while patients who were treated by EPCS required 
hospitalization for recurrent PSE every 8.38 years (p=0.003).  
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Fig. 1. Incidence and timing of recurrent PSE in patients who were randomized to EST 
(n=93) or EPCS (n=89) and survived >30 days and were discharged from the hospital. 
5.3 Cause of recurrent PSE 
Dietary indiscretion with regard to protein restriction was the most frequent cause of 
recurrent PSE in both groups more so in the patients treated by EPCS. Portal hypertension-
related UGI bleeding, usually from esophageal varices, was the main cause of recurrent PSE 
in 32% of the episodes experienced in patients treated by EST, and was a contributing cause 
in an additional 18%. Gastrointestinal bleeding was infrequently responsible for PSE in 
patients who underwent EPCS (p<0.001). Thus, gastrointestinal bleeding played a role in 57 
episodes of PSE in the EST group, compared to 8 episodes in the EPCS group, and 
undoubtedly was a major factor in the higher incidence of recurrent PSE following EST. 
Other conditions responsible for at least 10% of PSE episodes were infection, alcoholism, 
and uncontrolled diabetes.  
5.4 Relationship of recurrent PSE to survival  
In the EST group, patients with recurrent PSE lived a median 2.90 years while those who 
remained free of PSE lived a median 3.6 years, a longer period of time. This difference was 
significant (p=0.042) with a hazard ratio of death due to recurrent PSE of 1.60 (95% 
confidence interval 1.01, 2.56). It is not possible in the EST group to determine the effect of 
PSE on survival because of other factors, particularly recurrent BEV, which influenced 
survival.  
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In the EPCS group, patients who remained free of PSE lived a median 10.37 years, 
significantly longer than those with recurrent PSE who survived a median 5.18 years. The 
difference was significant (p=0.001). It is tempting to attribute the longer survival to 
freedom from PSE, but the many factors that affect survival make it inappropriate to single 
out PSE as the main determinant of life or death.  
The results with regard to PSE of our randomized controlled trial are contrary to 
conventional beliefs about both portacaval shunt and endoscopic sclerotherapy. The 
incidence of recurrent PSE during long-term follow-up of unselected patients treated by 
EPCS was only 15%, which was significantly lower than the 35% incidence of PSE following 
emergency and long-term EST. Moreover, every aspect of PSE was less severe following 
EPCS than after EST. The number of PSE episodes was fewer (94 vs. 179), the number of 
hospital readmissions for PSE was fewer (87 vs. 146), the calculated yearly frequency of PSE 
was lower, and the calculated per-patient average hospitalization for PSE was less frequent 
(once every 8.38 yr vs. once every 2.50 yr) in the EPCS group than in the EST patients.  
A number of factors appear to have played a role in causing PSE, but two of these factors 
were predominant. The first was dietary protein indiscretion. Despite concerted, repeated 
and often successful efforts to educate patients on limiting dietary protein intake to 60 g per 
day, dietary protein indiscretion was responsible for 75 of the 179 episodes of PSE in the EST 
group and 60 of the 94 episodes of PSE in the EPCS group. The second causative factor was 
recurrent variceal bleeding which was directly responsible for 32% of the episodes of PSE in 
patients treated by EST, and was a major contributing cause in an additional 18% of the 
episodes. In contrast, UGI bleeding at best may have been responsible for only 8 of the 94 
episodes of PSE in patients who had EPCS. It appears highly likely that the higher incidence 
of PSE following EST compared to EPCS was due to the failure of EST to achieve long-term 
control of BEV. It is noteworthy that resumption of alcoholism may have played a role in 
only 12% of the episodes of PSE. These results demonstrate that a low incidence of PSE is 
possible when patients are free of recurrent UGI bleeding, abstain from alcohol, and comply 
with a diet of moderate protein restriction.  
6. Portal-systemic encephalopathy in our RCT of TIPS versus emergency 
portacaval shunt 
We have completed a RCT of emergency TIPS versus EPCS that enrolled 154 unselected 
consecutive patients who have been followed up for 5 to 10 years. The results of this RCT 
have been submitted for publication (Orloff et al., 2011h; Orloff et al., 2011j). Transjugular 
intrahepatic portosystemic shunt, or TIPS, is a side-to-side portacaval shunt performed 
radiologically by a percutaneous approach. It is the most widely used form of portal 
decompression and is used to control BEV when other measures, such as endoscopic 
treatment and pharmacologic therapy, have failed. The major shortcomings of TIPS reported 
in numerous studies have been a high incidence of occlusion of the shunt and the frequent 
occurrence of PSE.  
In our RCT, regular follow-up to determine patency of the TIPS and EPCS revealed stenosis 
or occlusion of the TIPS in 84% of this group of patients. Patients treated by TIPS had a 
mean 2.1 episodes of TIPS stenosis or occlusion. Revision of the TIPS by balloon angioplasty 
or insertion of one or more additional stents was performed in 63% of the patients with TIPS 
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malfunction. The revisions failed in 80% of the patients. The consequences of TIPS 
malfunction were recurrent BEV and PSE. Durability of TIPS was disappointing. In marked 
contrast, EPCS remained permanently patent in 97% of the patients in that groups, as a 
result of which there was permanent prevention of recurrent BEV and a significantly lower 
incidence of PSE. In the overall, 61% of the patients treated by TIPS developed recurrent 
PSE, compared to 21% of the patients treated by EPCS. The three-fold greater incidence of 
recurrent PSE in the TIPS group was highly significant (p<0.001).  
In both of our recently reported RCTs, EPCS was a total shunt that involved a direct 
anastomosis between the portal vein and inferior vena cava. EPCS permanently controlled 
variceal bleeding, resulted in long-term survival that was substantially greater than that 
obtained by EST, and was followed by a relatively low rate of PSE that was less than one-
half the rate associated with EST. How do we account for the low incidence of PSE? We 
believe that a number of factors played an important role in the results achieved by EPCS in 
our study. First, and most important, EPCS was uniformly successful in preventing 
recurrent BEV, a frequent cause of PSE. Second, hepatic function improved and stabilized in 
a substantial majority of patients as a result of both freedom from bleeding and abstinence 
from alcohol, which was permanent in 62% of the patients. Third, follow-up evaluation and 
support was rigorous, frequent and lifelong in all patients. Fourth, follow-up included 
regular counseling by a dietitian on restriction of dietary protein intake to 60 g/day, an 
amount that is quite ample for nutrition and is compatible with an appetizing diet. A high 
level of patient compliance was obtained by repeated education about the importance of 
moderate protein restriction. Fifth, long-term patency and function of the portacaval shunt 
was obtained in 98% of patients. No one of these factors alone can account for the low 
incidence of PSE, but together they resulted in a rate of PSE that was less than one-half the 
rate associated with EST.  
7. Conclusions 
In these prospective randomized controlled trials of emergency treatment of acute bleeding 
esophageal or gastric varices in 4 separate studies involving 628 unselected, consecutive 
patients with cirrhosis of all grades of severity, EPCS was followed by a 15-21% incidence of 
recurrent PSE, which was significantly lower than the 35% incidence of PSE that followed 
emergency and long-term EST and the 61% incidence associated with TIPS. These results 
contradict the widespread belief that portal-systemic shunts are associated with a high 
incidence of PSE. Moreover, these results call into question the widespread practice of using 
portal-systemic shunt mainly or only as salvage for failure of endoscopic and pharmacologic 
therapy because of the belief that the superior control of variceal bleeding by surgery is 
offset by life-threatening PSE.  
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